TrialRheumatology (Oxford, England)2022

Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.

Charles G Peterfy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.